United States · FDA National Drug Code directory
Myfembree
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 72974-415_d0b51ef8-0118-4b78-a83f-73338d6dab9b
- Product NDC
- 72974-415
- Form
- TABLET, FILM COATED
- Composition / generic term
- relugolix, estradiol hemihydrate, and norethindrone acetate
- Labeler
- Sumitomo Pharma America, Inc
- Marketing category
- NDA
- Marketing start / end (source format)
- 20210526
- Source listing expiry
- 20261231
Source-listed ingredients
- RELUGOLIX — 40 mg/1
- ESTRADIOL HEMIHYDRATE — 1 mg/1
- NORETHINDRONE ACETATE — .5 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 28 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72974-415-01) · 72974-415-01
- 7 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72974-415-99) · 72974-415-99
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →